×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Executives Respond to the State of the Industry Report on Risk-Based Approaches in Clinical Trials: Opportunity or Threat?
Session Chair(s)
Dennis Salotti, MBA, MS
Senior Director and Head of Strategic Outsourcing and Clinical Innovation
Jazz Pharmaceuticals , United States
Part didactic presentation, part lively debate and discussion among an executive panel, dive deep into the state of risk in clinical trials and explore our data on risk assessment and risk-based approaches to clinical trial oversight and execution.
Learning Objective : Identify the most recent information regarding the state of the industry for familiarity, use, impact and satisfaction with risk assessment and risk-based approaches in clinical research; Develop new perspectives on how to shape their individual and organizational perspectives and positioning with respect to changing regulatory requirements and evolving risk landscape.
Speaker(s)
Panelist
Neil McCullough
ICON Clinical Research, United States
Executive Vice President, Clinical Quality and Compliance
Panelist
Elizabeth Luczak, MBA
Vertex Pharmaceuticals, United States
Vice President, R&D Quality Assurance
Have an account?